Product image of Imaplix (Apremilast) supplied by GNH India

Imaplix

Active Ingredient:
Apremilast
Origin:
EU

Imaplix (Apremilast)

Apremilast, the active ingredient in Imaplix, is a phosphodiesterase 4 (PDE4) inhibitor presented as an oral tablet for oral use. It is prescribed for adult patients with moderate to severe plaque psoriasis and for those with active psoriatic arthritis, providing a systemic treatment option without injection.

GNH India supplies Imaplix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable logistics for bulk and individual orders.

Manufacturer / TM Owner

Norameda Uab

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Imaplix (apremilast) is used to manage inflammatory skin and joint conditions mediated by the phosphodiesterase‑4 pathway.

  • Psoriasis: reduces plaque formation, scaling and erythema in moderate to severe disease.
  • Psoriatic arthritis: alleviates joint pain, swelling and improves physical function.
  • Moderate to severe disease: offers an oral systemic therapy alternative to injectable biologics.

How It Works

  • Apremilast selectively inhibits the intracellular enzyme phosphodiesterase 4, leading to increased cyclic adenosine monophosphate (cAMP) levels in immune cells. Elevated cAMP modulates the production of inflammatory cytokines such as TNF‑α, IL‑17 and IL‑23, thereby reducing the inflammatory response that drives plaque formation in psoriasis and joint inflammation in psoriatic arthritis. The effect is achieved without direct immunosuppression, allowing modulation of disease activity while preserving broader immune function.

Side Effects

Apremilast may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Diarrhea: loose stools, often transient.
  • Headache: mild tension‑type headaches.
  • Upper respiratory tract infection: cold‑like symptoms.
  • Weight loss: gradual decrease in body weight.
  • Vomiting: occasional episodes.

Serious or Rare Side Effects

  • Depression or suicidal thoughts: mood changes requiring immediate evaluation.
  • Severe allergic reaction: rash, swelling, or anaphylaxis.
  • Pancreatitis: abdominal pain with elevated enzymes.
  • Significant liver enzyme elevation: hepatitis risk.
  • Severe infections: opportunistic bacterial or fungal infections.
  • Cardiovascular events: rare cases of arrhythmia.

Precautions & Warnings

When prescribing Apremilast, clinicians should consider several safety precautions to minimize risk.

  • Pregnancy: safety not established; avoid unless potential benefit justifies risk.
  • Breastfeeding: unknown excretion; weigh benefits against possible infant exposure.
  • Renal impairment: assess kidney function; dose adjustment may be required.
  • Hepatic impairment: monitor liver enzymes regularly.
  • Concomitant antidepressants: observe for mood changes.
  • Store at ambient temperature: keep below 25 °C, retain original packaging and protect from moisture.

Avoid Interactions

Apremilast can interact with other medicines; some combinations should be avoided while others need careful monitoring.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce apremilast exposure.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): can increase apremilast levels and toxicity risk.
  • Anticoagulants (e.g., warfarin): potential for enhanced bleeding tendency.

Moderate Interactions (Monitor Closely)

  • Methotrexate: may increase hepatic toxicity; monitor liver function.
  • NSAIDs: additive gastrointestinal irritation.
  • Alcohol: may exacerbate liver enzyme elevations.

Frequently Asked Questions

Imaplix contains apremilast and is prescribed for adult patients with moderate to severe plaque psoriasis and for those with active psoriatic arthritis, providing an oral systemic option to control skin lesions and joint inflammation.

Apremilast selectively inhibits the enzyme phosphodiesterase 4, which raises intracellular cAMP levels. The increased cAMP modulates immune cell activity and reduces the production of inflammatory cytokines such as TNF‑α, IL‑17 and IL‑23, thereby dampening the inflammatory processes that drive psoriasis and psoriatic arthritis.

The dosage of Imaplix is determined by the prescribing physician based on the patient’s clinical condition, renal and hepatic function, and other individual factors. The prescriber will provide specific dosing instructions and any necessary titration schedule.

Safety data for apremilast in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy unless the potential benefit outweighs the risk, and breastfeeding is not recommended without careful consideration of possible infant exposure.

To request Imaplix, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imaplix (apremilast) is an oral phosphodiesterase 4 inhibitor, differing from biologic agents that target specific cytokines. It offers a non‑injectable option with a distinct safety profile, making it suitable for patients who prefer oral therapy or who have contraindications to biologics.

Imaplix tablets should be stored at ambient temperature, preferably below 25 °C. Keep the medication in its original packaging, protect it from moisture and direct sunlight, and store out of reach of children.

Imaplix is taken orally, usually once daily with or without food, as directed by the prescribing healthcare professional. Tablets should be swallowed whole with water and not crushed or chewed unless otherwise instructed.

Serious risks include the potential for depression, suicidal thoughts, severe allergic reactions, pancreatitis, significant liver enzyme elevations, and rare opportunistic infections. Patients should be monitored regularly for mood changes and any signs of severe adverse events.

Imaplix should be avoided in patients with known hypersensitivity to apremilast or any tablet excipients, in those with uncontrolled severe hepatic impairment, and in individuals where the risk of depression or suicidal ideation outweighs the therapeutic benefit.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Apremilast

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT